William Colomb, MD
Psychiatry · Mandeville, LANPI 1235279167
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,645 of the $117,013 with a category attached, or 90.3%. Supernus Pharmaceuticals, Inc. accounts for 92.8% of it on its own, with 9 other manufacturers making up the rest. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $319.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$109K
- Ironshore Pharmaceuticals Inc.$6K
- AbbVie$1K
- Noven Therapeutics, LLC$192
- Alkermes, Inc.$125
- Corium, LLC$106
- plus $190 from 4 others
What the payments were for
- Speaking & faculty fees$105,64590%
- Travel & lodging$5,5085%
- Food & beverage$5,8075%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 215 | $108,579 |
| Ironshore Pharmaceuticals Inc. | 17 | $6,421 |
| AbbVie(2 entities) | 106 | $1,400 |
| Noven Therapeutics, LLC | 13 | $192 |
| Alkermes, Inc. | 1 | $125 |
| Corium, LLC | 5 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Lundbeck LLC | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| Bausch Health US, LLC | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$102,009
- Jornay PM 20mg capsules (Bottle of 100)$5,833
- LYBALVI$500
- VRAYLAR$346
How this compares
$117,013 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 37 | $63,897 |
| VraylarCariprazine Hcl | 22 | $31,412 |
| AuvelityDextromethorphan Hbr/Bupropion | 22 | $27,982 |
| RexultiBrexpiprazole | 12 | $17,026 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,743 |
| Seroquel XrQuetiapine Fumarate | 20 | $10,995 |
| Lurasidone Hcl | 49 | $8,161 |
| AdderallDextroamphetamine/Amphetamine | 13 | $8,036 |
| Risperidone OdtRisperidone | 12 | $7,791 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,540 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $4,845 |
| Clonidine | 34 | $3,186 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 31 | $2,652 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 120 | $2,614 |
| Carbamazepine | 24 | $2,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $47 | $63,89737 claims |
| AbbVieVraylar | $1,400 | $31,41222 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall, Vyvanse | $63 | $25,31950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Mandeville
- Roger BrownMandeville$216K
- Shanmugan ShanthaMandeville$7K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Abdul KhanBaton Rouge$156K
- Andrew MorsonNew Orleans$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.